ArticleDermatology research and practice2010
Stress as a possible mechanism in melanoma progression.
Article in Dermatology research and practice, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- The association between partner bereavement and melanoma: cohort studies in the U.K. and Denmark.The British journal of dermatology · 2020Pooled it
- Longitudinal change in telomere length and the chronic stress response in a randomized pilot biobehavioral clinical study: implications for cancer prevention.Cancer prevention research (Philadelphia, Pa.) · 2012Trial
- Integrative bioinformatic and experimental analysis reveals prognostic and immunological roles of psychological stress-related genes in skin cutaneous melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The Effectiveness of Group and Individual Training in Emotional Freedom Techniques for Patients in Remission from Melanoma: A Randomized Controlled Trial.Healthcare (Basel, Switzerland) · 2025Article
- Bioadhesive Eudragit RLPharmaceutics · 2025Article
- Distress and Its Determinants in 820 Consecutive Melanoma Patients.Cancer medicine · 2025Article
- Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Review
- Review: The Key Factors to Melanomagenesis.Life (Basel, Switzerland) · 2023Review
- Neuroendocrine Factors in Melanoma Pathogenesis.Cancers · 2021Review
- Anxiety and depression after diagnosis of high-risk primary cutaneous melanoma: a 4-year longitudinal study.Journal of cancer survivorship : research and practice · 2020Article
- The Role of β-Blockers in Melanoma.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- The Autonomic Regulation of Tumor Growth and the Missing Links.Frontiers in oncology · 2020Review
- Specific Urinary Metabolites in Malignant Melanoma.Medicina (Kaunas, Lithuania) · 2019Article
- Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study.JAMA oncology · 2018Article
- Neuroendocrine factors: The missing link in non‑melanoma skin cancer (Review).Oncology reports · 2017Review
- Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of melanoma, the most aggressive type of cutaneous malignant tumor, is currently on the rise. Treatment in advanced stages is still unsuccessful compared with other malignant tumors, thus it is important to indentify the key mechanisms responsible for melanoma progression and metastasis. Genetic and molecular components, in particular, that are up- or downregulated in melanoma cells, affect the invasive potential of melanoma. Another possible important cofactor highlighted by recent studies is chronic stress, involving environmental and psychological factors, which can be an important cofactor in not only cancer progression in general but also in melanoma spreading. The negative effects of chronic stress have been evaluated epidemiologically in patients with breast and prostate cancer. In particular, the effects of stress mediators, namely, catecholamines have been studied on various human malignancies, including melanoma and have highlighted a significant increase of progression-related molecules. As such, this could be the starting point for a new approach in the treatment of advanced melanoma, in which the negative effects of stress are reduced or blocked.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.